Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10607545 | 0.82 | MMP2 (0.39) | POLBPDK2PDK4ALDH1A1GAA | |
| SCHEMBL10531285 | 0.77 | ELOVL6 (0.42) | PGRELOVL6 | |
| SCHEMBL4120633 | 0.77 | ELOVL6 (0.42) | ALDH1A1HSD11B1PGRELOVL6AKR1B1 | |
| SCHEMBL3873417 | 0.77 | ELOVL6 (0.42) | PGRELOVL6 | |
| SCHEMBL13126045 | 0.77 | ELOVL6 (0.45) | POLBPDK2PDK4ALDH1A1PGR | |
| SCHEMBL10960160 | 0.77 | ELOVL6 (0.45) | PGRELOVL6 | |
| SCHEMBL631642 | 0.76 | PGR (0.55) | PDK2PDK4ALDH1A1PGR | |
| SCHEMBL4847776 | 0.75 | ELOVL6 (0.38) | HSD11B1PGRELOVL6HTT | |
| SCHEMBL10956566 | 0.74 | PGR (0.50) | ALDH1A1PGRELOVL6AKR1B1GAA | |
| SCHEMBL4847852 | 0.73 | ELOVL6 (0.43) | PGRELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354915-B2 | 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH | 2005-04-21 | — | — | US | disclosed |
| US-4831027-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1989-05-16 | — | — | US | disclosed |
| EP-0263352-A1 | Imidazo-benzoxazinones, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | POLB 3630/4885PDK2 2163/4885PDK4 1893/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | POLB 3630/4885PDK2 2163/4885PDK4 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.